PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours ; volume:12 ; number:1 ; day:25 ; month:10 ; year:2012 ; pages:1-10 ; date:12.2012
BMC cancer ; 12, Heft 1 (25.10.2012), 1-10, 12.2012
- Creator
-
McKeage, Mark J.
- Contributor
-
Jameson, Michael B.
Ramanathan, Ramesh K.
Rajendran, Joseph
Gu, Yongchuan
Wilson, William R.
Melink, Teresa J.
Tchekmedyian, N Simon
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-12-496
- URN
-
urn:nbn:de:1111-201603041960
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- McKeage, Mark J.
- Jameson, Michael B.
- Ramanathan, Ramesh K.
- Rajendran, Joseph
- Gu, Yongchuan
- Wilson, William R.
- Melink, Teresa J.
- Tchekmedyian, N Simon
- SpringerLink (Online service)
Other Objects (12)
A Novel Fluorescent Gemcitabine Prodrug That Follows a Nucleoside Transporter‐Independent Internalization and Bears Enhanced Therapeutic Efficacy With Respect to Gemcitabine
Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma
A rare presentation of carcinosarcoma of the bone in a young female; response with gemcitabine and docetaxel
Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine
Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
Gemcitabine and Docetaxel for Epithelioid Sarcoma : Results from a Retrospective, Multi-Institutional Analysis
Gemcitabine and Docetaxel for Epithelioid Sarcoma: Results from a Retrospective, Multi-Institutional Analysis
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors
Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer
Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone
Engineering Extracellular Vesicles with the Tools of Enzyme Prodrug Therapy
Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
A Novel Fluorescent Gemcitabine Prodrug That Follows a Nucleoside Transporter‐Independent Internalization and Bears Enhanced Therapeutic Efficacy With Respect to Gemcitabine
Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma
A rare presentation of carcinosarcoma of the bone in a young female; response with gemcitabine and docetaxel
Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine
Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
Gemcitabine and Docetaxel for Epithelioid Sarcoma : Results from a Retrospective, Multi-Institutional Analysis
Gemcitabine and Docetaxel for Epithelioid Sarcoma: Results from a Retrospective, Multi-Institutional Analysis
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors
Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer
Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone
Engineering Extracellular Vesicles with the Tools of Enzyme Prodrug Therapy
Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
A Novel Fluorescent Gemcitabine Prodrug That Follows a Nucleoside Transporter‐Independent Internalization and Bears Enhanced Therapeutic Efficacy With Respect to Gemcitabine
Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma
A rare presentation of carcinosarcoma of the bone in a young female; response with gemcitabine and docetaxel
Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine
Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
Gemcitabine and Docetaxel for Epithelioid Sarcoma : Results from a Retrospective, Multi-Institutional Analysis
Gemcitabine and Docetaxel for Epithelioid Sarcoma: Results from a Retrospective, Multi-Institutional Analysis
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors
Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer
Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone
Engineering Extracellular Vesicles with the Tools of Enzyme Prodrug Therapy